Allergan sued rival Prollenium Medical Technologies in federal court for patent royalties on sales of its Revanesse Versa+ wrinkle-filler, claiming Versa+ infringes two of Allergan's patents for Juvedérm.
The patents cover formulations for and methods of manufacturing the filler compositions that include lidocaine, an anesthetic, added by Allergan as a way to take some of the sting out of the injection process. Juvedérm products had U.S. sales of $389.8 million during the first nine months of 2018.
Allergan is demanding cash compensation from Canada-based Prollenium and an order blocking sales of Versa+.
Read the Bloomberg coverage